So sánh Venetoclax và azacitidine với hóa trị khởi đầu cho bệnh nhân mới được chẩn đoán mắc bệnh bạch cầu myeloid cấp tính

Estey, 2020, Acute myeloid leukemia: 2021 update on risk-stratification and management, Am J Hematol., 95, 1368, 10.1002/ajh.25975 DiNardo, 2020, Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N Engl J Med., 383, 617, 10.1056/NEJMoa2012971 DiNardo, 2019, Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood., 133, 7, 10.1182/blood-2018-08-868752 DiNardo, 2018, Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study, Lancet Oncol., 19, 216, 10.1016/S1470-2045(18)30010-X Pollyea, 2021, Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study, Am J Hematol., 96, 208, 10.1002/ajh.26039 Michaelis, 2019, Venetoclax in AML: aiming for “just right”, Blood., 133, 3, 10.1182/blood-2018-11-883454 Pollyea, 2017, The case for abandoning induction chemotherapy, The Hematologist., 14, 10.1182/hem.V14.3.7298 Pollyea, 2019, Acute myeloid leukemia drug development in the post-venetoclax era, Am J Hematol., 94, 959, 10.1002/ajh.25556 Pei, 2020, Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia, Cancer Discov., 10, 536, 10.1158/2159-8290.CD-19-0710 Döhner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood., 129, 424, 10.1182/blood-2016-08-733196 Bennett, 1976, Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group, Br J Haematol., 33, 451, 10.1111/j.1365-2141.1976.tb03563.x Abbott, 2021, The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia, Leuk Lymphoma., 62, 1466, 10.1080/10428194.2020.1864358 D’Agostino, 1998, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, Stat Med., 17, 2265, 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B Benjamini, 1995, Controlling the false discovery rate - a practical and powerful approach to multiple testing, J R Stat Soc Series B Stat Methodol., 57, 289 Shaffer, 1995, Multiple hypothesis testing, Annu Rev Psychol., 46, 561, 10.1146/annurev.ps.46.020195.003021 Tang, 2009, AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations, Blood., 114, 5352, 10.1182/blood-2009-05-223784 Mendler, 2012, RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures, J Clin Oncol., 30, 3109, 10.1200/JCO.2011.40.6652 Gaidzik, 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group, J Clin Oncol., 29, 1364, 10.1200/JCO.2010.30.7926 Gaidzik, 2016, RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features, Leukemia., 30, 2160, 10.1038/leu.2016.126 Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med., 374, 2209, 10.1056/NEJMoa1516192 Metzeler, 2016, Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia, Blood., 128, 686, 10.1182/blood-2016-01-693879 Klepin, 2016, Definition of unfit for standard acute myeloid leukemia therapy, Curr Hematol Malig Rep., 11, 537, 10.1007/s11899-016-0348-8 Chen, 2020, Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?, Hematology Am Soc Hematol Educ Program., 2020, 41, 10.1182/hematology.2020000087 National Cancer Research Institute Daver, 2020, New directions for emerging therapies in acute myeloid leukemia: the next chapter, Blood Cancer J., 10, 107, 10.1038/s41408-020-00376-1 Simon, 2020, High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML, Blood., 135, 1882, 10.1182/blood.2019003357 Mardis, 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome, N Engl J Med., 361, 1058, 10.1056/NEJMoa0903840 Miles, 2020, Single-cell mutation analysis of clonal evolution in myeloid malignancies, Nature., 587, 477, 10.1038/s41586-020-2864-x Esparza, 2020, Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia, Br J Haematol., 188, 173, 10.1111/bjh.16235 Wesely, 2020, Acute myeloid leukemia iPSCs reveal a role for RUNX1 in the maintenance of human leukemia stem cells, Cell Rep., 31, 107688, 10.1016/j.celrep.2020.107688 Pollyea, 2018, Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia, Nat Med., 24, 1859, 10.1038/s41591-018-0233-1 Jones, 2018, Inhibition of amino acid metabolism selectively targets human leukemia stem cells [published correction appears in Cancer Cell. 2019;35(2):333-335], Cancer Cell., 34, 724, 10.1016/j.ccell.2018.10.005 Jones, 2019, Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II, Blood., 134, 389, 10.1182/blood.2019898114 Kuusanmaki, 2020, Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia, Haematologica., 105, 708, 10.3324/haematol.2018.214882 Nechiporuk, 2019, The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells, Cancer Discov., 9, 910, 10.1158/2159-8290.CD-19-0125 DiNardo, 2020, Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML, Blood., 135, 791, 10.1182/blood.2019003988 Stevens, 2020, Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells, Nat Can., 1, 1176, 10.1038/s43018-020-00126-z Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood., 96, 4075, 10.1182/blood.V96.13.4075 Breems, 2008, Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype, J Clin Oncol., 26, 4791, 10.1200/JCO.2008.16.0259 Othus, 2019, Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies, Leukemia., 33, 371, 10.1038/s41375-018-0275-x Zeidan, 2020, Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States, Blood Adv., 4, 1615, 10.1182/bloodadvances.2020001728 Maiti, 2021, Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality, Am J Hematol., 96, 282, 10.1002/ajh.26061 Begna, 2021, Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy, Am J Hematol., 96, E108, 10.1002/ajh.26112 Lachowiez, 2020, Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens, Blood Adv., 4, 1311, 10.1182/bloodadvances.2019001267 Konopleva, 2016, Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia, Cancer Discov., 6, 1106, 10.1158/2159-8290.CD-16-0313 Venugopal, 2021, Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia, Am J Hematol., 96, E154, 10.1002/ajh.26122